You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 793 Combined administration of the dual A2aR/A2bR antagonist etrumadenant with a reduced chemotherapy regimen leads to enhanced tumor efficacy and survival

Article Text

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
793 Combined administration of the dual A2aR/A2bR antagonist etrumadenant with a reduced chemotherapy regimen leads to enhanced tumor efficacy and survival

https://doi.org/10.1136/jitc-2023-SITC2023.0793

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.